Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Staphylococcus aureus | 62 | 2024 | 1456 | 10.410 |
Why?
|
Quinolones | 35 | 2021 | 375 | 6.810 |
Why?
|
Bacterial Proteins | 59 | 2024 | 3815 | 6.000 |
Why?
|
Drug Resistance, Bacterial | 48 | 2021 | 1043 | 5.150 |
Why?
|
Ciprofloxacin | 33 | 2021 | 311 | 5.100 |
Why?
|
Anti-Infective Agents | 60 | 2023 | 978 | 4.950 |
Why?
|
Staphylococcal Infections | 29 | 2024 | 1404 | 4.690 |
Why?
|
Anti-Bacterial Agents | 87 | 2024 | 7346 | 4.640 |
Why?
|
DNA Gyrase | 22 | 2021 | 85 | 4.620 |
Why?
|
Escherichia coli Proteins | 17 | 2022 | 1059 | 4.140 |
Why?
|
Fluoroquinolones | 33 | 2016 | 307 | 4.030 |
Why?
|
Plasmids | 36 | 2022 | 2276 | 3.990 |
Why?
|
Membrane Transport Proteins | 15 | 2024 | 1036 | 3.860 |
Why?
|
Microbial Sensitivity Tests | 61 | 2024 | 1911 | 3.600 |
Why?
|
Gene Expression Regulation, Bacterial | 23 | 2024 | 1122 | 3.510 |
Why?
|
Escherichia coli | 49 | 2024 | 4210 | 3.430 |
Why?
|
DNA Topoisomerase IV | 20 | 2021 | 42 | 2.900 |
Why?
|
Drug Resistance, Multiple, Bacterial | 19 | 2024 | 583 | 2.850 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 14 | 2017 | 692 | 2.370 |
Why?
|
Cross Infection | 18 | 2020 | 1428 | 1.950 |
Why?
|
Enterobacteriaceae | 9 | 2017 | 171 | 1.620 |
Why?
|
DNA Topoisomerases, Type II | 19 | 2005 | 124 | 1.590 |
Why?
|
Abscess | 9 | 2018 | 605 | 1.450 |
Why?
|
Tetracycline | 6 | 2024 | 225 | 1.410 |
Why?
|
Klebsiella pneumoniae | 8 | 2024 | 252 | 1.410 |
Why?
|
Drug Resistance, Microbial | 30 | 2020 | 856 | 1.390 |
Why?
|
Topoisomerase II Inhibitors | 16 | 2015 | 96 | 1.350 |
Why?
|
Multidrug Resistance-Associated Proteins | 9 | 2024 | 101 | 1.290 |
Why?
|
Enterobacteriaceae Infections | 7 | 2017 | 189 | 1.240 |
Why?
|
Enterococcus | 6 | 2017 | 160 | 1.180 |
Why?
|
Genes, Bacterial | 14 | 2018 | 1066 | 1.160 |
Why?
|
Genetic Fitness | 2 | 2019 | 114 | 1.150 |
Why?
|
Serratia marcescens | 3 | 2023 | 48 | 1.130 |
Why?
|
Pseudomonas aeruginosa | 8 | 2024 | 1266 | 1.080 |
Why?
|
Infection Control | 7 | 2022 | 976 | 0.980 |
Why?
|
Urinary Tract Infections | 9 | 2020 | 815 | 0.980 |
Why?
|
Enterobacter cloacae | 2 | 2023 | 22 | 0.970 |
Why?
|
Phenazines | 1 | 2024 | 57 | 0.950 |
Why?
|
Clostridium botulinum | 2 | 2014 | 21 | 0.930 |
Why?
|
Acinetobacter baumannii | 3 | 2020 | 115 | 0.920 |
Why?
|
Botulism | 2 | 2014 | 21 | 0.920 |
Why?
|
Staphylococcal Skin Infections | 7 | 2014 | 77 | 0.860 |
Why?
|
Acetyltransferases | 4 | 2009 | 231 | 0.860 |
Why?
|
Equipment Contamination | 3 | 2019 | 180 | 0.850 |
Why?
|
Bacteria | 14 | 2023 | 2174 | 0.840 |
Why?
|
Acinetobacter Infections | 2 | 2020 | 71 | 0.840 |
Why?
|
Bacteriological Techniques | 2 | 2014 | 280 | 0.810 |
Why?
|
Botulinum Toxins | 2 | 2014 | 189 | 0.800 |
Why?
|
Teichoic Acids | 2 | 2019 | 70 | 0.790 |
Why?
|
Vibrio vulnificus | 1 | 2021 | 10 | 0.770 |
Why?
|
Norfloxacin | 10 | 2010 | 24 | 0.730 |
Why?
|
Escherichia coli Infections | 6 | 2020 | 524 | 0.710 |
Why?
|
Quinolines | 5 | 2011 | 754 | 0.710 |
Why?
|
Gram-Positive Bacterial Infections | 5 | 2014 | 338 | 0.710 |
Why?
|
Epithelial Cells | 3 | 2017 | 3668 | 0.710 |
Why?
|
Vancomycin Resistance | 5 | 2012 | 126 | 0.700 |
Why?
|
Polymerase Chain Reaction | 8 | 2015 | 6067 | 0.700 |
Why?
|
Gram-Negative Bacteria | 3 | 2019 | 273 | 0.700 |
Why?
|
Vancomycin | 3 | 2017 | 500 | 0.690 |
Why?
|
Toll-Like Receptor 2 | 2 | 2019 | 347 | 0.690 |
Why?
|
Congo Red | 1 | 2019 | 48 | 0.670 |
Why?
|
Tunicamycin | 1 | 2019 | 108 | 0.660 |
Why?
|
Pseudomonas Infections | 1 | 2024 | 618 | 0.660 |
Why?
|
Genes, Regulator | 3 | 2011 | 374 | 0.650 |
Why?
|
Aza Compounds | 3 | 2011 | 34 | 0.650 |
Why?
|
DNA, Bacterial | 10 | 2018 | 1451 | 0.640 |
Why?
|
Duodenoscopes | 1 | 2019 | 44 | 0.640 |
Why?
|
Fosfomycin | 1 | 2018 | 24 | 0.630 |
Why?
|
Methicillin | 2 | 2017 | 62 | 0.610 |
Why?
|
Bacterial Infections | 10 | 2017 | 1401 | 0.600 |
Why?
|
beta-Lactams | 4 | 2024 | 157 | 0.600 |
Why?
|
Ornithine | 1 | 2017 | 79 | 0.590 |
Why?
|
Citrates | 1 | 2017 | 136 | 0.570 |
Why?
|
Organizational Policy | 2 | 2017 | 428 | 0.570 |
Why?
|
Transcription, Genetic | 6 | 2017 | 7574 | 0.570 |
Why?
|
Topoisomerase Inhibitors | 1 | 2016 | 19 | 0.560 |
Why?
|
Gram-Negative Bacterial Infections | 3 | 2019 | 239 | 0.560 |
Why?
|
Cation Transport Proteins | 1 | 2019 | 324 | 0.550 |
Why?
|
ATP-Binding Cassette Transporters | 3 | 2017 | 558 | 0.530 |
Why?
|
beta-Lactamases | 6 | 2024 | 302 | 0.520 |
Why?
|
Hospitals, General | 2 | 2017 | 767 | 0.520 |
Why?
|
Mutation | 40 | 2021 | 29764 | 0.520 |
Why?
|
Phagosomes | 1 | 2017 | 200 | 0.510 |
Why?
|
Ofloxacin | 7 | 2002 | 65 | 0.510 |
Why?
|
Molecular Sequence Data | 23 | 2014 | 17607 | 0.500 |
Why?
|
Catheter-Related Infections | 2 | 2015 | 271 | 0.500 |
Why?
|
Naphthyridines | 5 | 2005 | 137 | 0.500 |
Why?
|
Vibrio | 2 | 2013 | 43 | 0.490 |
Why?
|
Surgical Wound Infection | 10 | 2020 | 1516 | 0.490 |
Why?
|
4-Quinolones | 17 | 2003 | 25 | 0.480 |
Why?
|
Quinine | 3 | 2021 | 51 | 0.480 |
Why?
|
Carbapenems | 3 | 2022 | 123 | 0.480 |
Why?
|
Promoter Regions, Genetic | 12 | 2020 | 5787 | 0.470 |
Why?
|
History of Medicine | 1 | 2014 | 42 | 0.460 |
Why?
|
Chromosomes, Bacterial | 7 | 2011 | 280 | 0.460 |
Why?
|
Hydroxyquinolines | 1 | 2013 | 17 | 0.450 |
Why?
|
Protein Binding | 11 | 2019 | 9300 | 0.440 |
Why?
|
Imidazoles | 1 | 2019 | 1175 | 0.430 |
Why?
|
R Factors | 2 | 2017 | 44 | 0.420 |
Why?
|
Host-Pathogen Interactions | 2 | 2021 | 1443 | 0.410 |
Why?
|
Professional Competence | 1 | 2015 | 432 | 0.400 |
Why?
|
Citrobacter | 1 | 2011 | 4 | 0.400 |
Why?
|
Quorum Sensing | 1 | 2013 | 133 | 0.400 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 8 | 2011 | 4569 | 0.390 |
Why?
|
Oxacillin | 2 | 2024 | 41 | 0.390 |
Why?
|
Base Sequence | 13 | 2020 | 12439 | 0.380 |
Why?
|
Shewanella | 1 | 2010 | 12 | 0.370 |
Why?
|
Patient Transfer | 2 | 2017 | 776 | 0.370 |
Why?
|
Coumarins | 5 | 1998 | 119 | 0.370 |
Why?
|
Babesiosis | 1 | 2012 | 92 | 0.370 |
Why?
|
Trans-Activators | 3 | 2017 | 2855 | 0.370 |
Why?
|
beta-Lactam Resistance | 2 | 2024 | 74 | 0.360 |
Why?
|
Nasal Mucosa | 1 | 2014 | 413 | 0.360 |
Why?
|
Carrier State | 1 | 2014 | 523 | 0.350 |
Why?
|
Nafcillin | 2 | 2024 | 24 | 0.350 |
Why?
|
Genetic Complementation Test | 4 | 2017 | 555 | 0.350 |
Why?
|
Rabies virus | 1 | 2009 | 36 | 0.340 |
Why?
|
Oxidoreductases | 1 | 2012 | 410 | 0.340 |
Why?
|
Salmonella enterica | 2 | 2006 | 75 | 0.330 |
Why?
|
Ceftazidime | 2 | 2024 | 57 | 0.330 |
Why?
|
Rabies | 1 | 2009 | 54 | 0.330 |
Why?
|
DNA-Binding Proteins | 5 | 2020 | 9561 | 0.330 |
Why?
|
Virulence Factors | 1 | 2012 | 507 | 0.320 |
Why?
|
Gene Expression Regulation, Enzymologic | 2 | 2012 | 1172 | 0.320 |
Why?
|
Antibiotic Prophylaxis | 2 | 2020 | 634 | 0.320 |
Why?
|
Novobiocin | 6 | 2015 | 35 | 0.320 |
Why?
|
Humans | 114 | 2024 | 756111 | 0.320 |
Why?
|
Methicillin Resistance | 6 | 2015 | 199 | 0.310 |
Why?
|
Recombinant Fusion Proteins | 2 | 2015 | 3725 | 0.310 |
Why?
|
Gene Expression | 2 | 2013 | 7582 | 0.310 |
Why?
|
Repressor Proteins | 4 | 2015 | 2972 | 0.300 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2013 | 610 | 0.300 |
Why?
|
Outpatients | 3 | 2020 | 1593 | 0.300 |
Why?
|
Nocardia Infections | 2 | 1998 | 18 | 0.300 |
Why?
|
Iron | 4 | 2020 | 1780 | 0.300 |
Why?
|
Skin Diseases, Infectious | 3 | 2021 | 74 | 0.300 |
Why?
|
Conjugation, Genetic | 7 | 2009 | 121 | 0.300 |
Why?
|
Cloning, Molecular | 7 | 2015 | 4171 | 0.290 |
Why?
|
Structure-Activity Relationship | 9 | 2021 | 3087 | 0.290 |
Why?
|
Sentinel Surveillance | 3 | 2018 | 287 | 0.290 |
Why?
|
Cold Temperature | 1 | 2010 | 777 | 0.280 |
Why?
|
Enterococcus faecium | 2 | 1998 | 100 | 0.280 |
Why?
|
Transcription Factors | 4 | 2020 | 12069 | 0.280 |
Why?
|
Electrophoretic Mobility Shift Assay | 3 | 2014 | 296 | 0.270 |
Why?
|
Stress, Physiological | 1 | 2014 | 1393 | 0.270 |
Why?
|
Klebsiella Infections | 2 | 2005 | 147 | 0.270 |
Why?
|
Central Nervous System | 3 | 2009 | 1332 | 0.270 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 2 | 2008 | 112 | 0.260 |
Why?
|
Communicable Diseases | 1 | 2014 | 878 | 0.260 |
Why?
|
Models, Theoretical | 1 | 2017 | 3561 | 0.250 |
Why?
|
DNA Primers | 3 | 2021 | 2810 | 0.250 |
Why?
|
Microbial Viability | 2 | 2017 | 237 | 0.240 |
Why?
|
Amino Acid Sequence | 13 | 2011 | 13425 | 0.240 |
Why?
|
Patient Admission | 1 | 2012 | 1383 | 0.240 |
Why?
|
Colectomy | 2 | 2020 | 691 | 0.240 |
Why?
|
Boston | 9 | 2020 | 9259 | 0.240 |
Why?
|
Community-Acquired Infections | 4 | 2020 | 458 | 0.240 |
Why?
|
Protein Processing, Post-Translational | 2 | 2012 | 1960 | 0.240 |
Why?
|
DNA Transposable Elements | 3 | 2017 | 752 | 0.240 |
Why?
|
Pyocyanine | 1 | 2024 | 20 | 0.230 |
Why?
|
Meningitis, Viral | 1 | 2004 | 50 | 0.230 |
Why?
|
Enzymes | 1 | 2005 | 262 | 0.230 |
Why?
|
Protein Kinases | 2 | 2022 | 1611 | 0.230 |
Why?
|
Meningitis, Aseptic | 1 | 2004 | 59 | 0.230 |
Why?
|
Disease Outbreaks | 5 | 2022 | 1746 | 0.230 |
Why?
|
Soft Tissue Infections | 3 | 2012 | 165 | 0.230 |
Why?
|
Pyrrolidines | 1 | 2005 | 337 | 0.230 |
Why?
|
Cellulitis | 3 | 2016 | 208 | 0.220 |
Why?
|
Sequence Analysis, DNA | 6 | 2020 | 4703 | 0.220 |
Why?
|
Vibrio cholerae | 1 | 2009 | 797 | 0.220 |
Why?
|
Biological Transport, Active | 4 | 2006 | 328 | 0.220 |
Why?
|
DNA Topoisomerases | 1 | 2003 | 4 | 0.220 |
Why?
|
Ceftriaxone | 1 | 2023 | 172 | 0.210 |
Why?
|
Herpesvirus 2, Human | 1 | 2004 | 190 | 0.210 |
Why?
|
Mice | 16 | 2023 | 80709 | 0.210 |
Why?
|
Ambulatory Care | 1 | 2014 | 2763 | 0.210 |
Why?
|
Population Surveillance | 5 | 2012 | 2608 | 0.210 |
Why?
|
Phylogeny | 3 | 2020 | 2754 | 0.210 |
Why?
|
Immunologic Factors | 1 | 2012 | 1580 | 0.210 |
Why?
|
Chloramphenicol | 2 | 2023 | 70 | 0.210 |
Why?
|
Proteolipids | 1 | 2002 | 112 | 0.200 |
Why?
|
Cytoplasmic Vesicles | 1 | 2002 | 73 | 0.200 |
Why?
|
Animals | 31 | 2023 | 167069 | 0.200 |
Why?
|
Gloves, Protective | 1 | 2001 | 23 | 0.200 |
Why?
|
Alleles | 8 | 2011 | 6886 | 0.200 |
Why?
|
Mupirocin | 1 | 2021 | 54 | 0.200 |
Why?
|
Reimbursement, Incentive | 1 | 2007 | 539 | 0.190 |
Why?
|
Korea | 2 | 2013 | 96 | 0.190 |
Why?
|
Gram-Positive Bacteria | 1 | 2002 | 179 | 0.190 |
Why?
|
Topoisomerase I Inhibitors | 2 | 1999 | 74 | 0.190 |
Why?
|
Gene Transfer, Horizontal | 1 | 2022 | 144 | 0.190 |
Why?
|
Stethoscopes | 1 | 2001 | 30 | 0.190 |
Why?
|
Encephalomyelitis, Autoimmune, Experimental | 1 | 2007 | 810 | 0.190 |
Why?
|
Anthozoa | 1 | 2021 | 65 | 0.190 |
Why?
|
Protective Clothing | 1 | 2001 | 103 | 0.190 |
Why?
|
Sequence Analysis | 1 | 2021 | 238 | 0.190 |
Why?
|
Quality Indicators, Health Care | 2 | 2011 | 1818 | 0.190 |
Why?
|
Arthroplasty, Replacement, Hip | 3 | 2011 | 1394 | 0.190 |
Why?
|
Rec A Recombinases | 2 | 2015 | 48 | 0.180 |
Why?
|
Herpes Simplex | 1 | 2004 | 473 | 0.180 |
Why?
|
Antibodies, Viral | 2 | 2009 | 3126 | 0.180 |
Why?
|
Blood-Brain Barrier | 1 | 2007 | 1016 | 0.180 |
Why?
|
Chlorhexidine | 1 | 2021 | 160 | 0.180 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2012 | 4342 | 0.180 |
Why?
|
Bacteriolysis | 1 | 2000 | 51 | 0.180 |
Why?
|
Genome, Viral | 2 | 2021 | 655 | 0.180 |
Why?
|
Hydrogen-Ion Concentration | 4 | 2014 | 2513 | 0.180 |
Why?
|
Hospitals | 6 | 2019 | 3926 | 0.180 |
Why?
|
Oxygen | 1 | 2012 | 4187 | 0.180 |
Why?
|
Aspergillus fumigatus | 1 | 2021 | 156 | 0.180 |
Why?
|
Bacterial Adhesion | 2 | 2003 | 306 | 0.170 |
Why?
|
Drug Resistance, Multiple | 2 | 2002 | 254 | 0.170 |
Why?
|
Operon | 1 | 2020 | 367 | 0.170 |
Why?
|
Patient Isolation | 1 | 2020 | 100 | 0.170 |
Why?
|
5' Untranslated Regions | 1 | 2001 | 255 | 0.170 |
Why?
|
Ultraviolet Therapy | 1 | 2020 | 84 | 0.170 |
Why?
|
Burn Units | 1 | 2020 | 140 | 0.170 |
Why?
|
Mycoses | 2 | 2017 | 383 | 0.170 |
Why?
|
Porphyrins | 1 | 2021 | 352 | 0.170 |
Why?
|
Mitomycin | 2 | 2011 | 262 | 0.170 |
Why?
|
Integration Host Factors | 1 | 2018 | 12 | 0.160 |
Why?
|
Colistin | 1 | 2019 | 45 | 0.160 |
Why?
|
Cephalosporins | 2 | 2021 | 202 | 0.160 |
Why?
|
Spinal Cord | 1 | 2007 | 1808 | 0.160 |
Why?
|
Disease Models, Animal | 8 | 2018 | 18009 | 0.160 |
Why?
|
Lac Operon | 1 | 2018 | 237 | 0.160 |
Why?
|
Bacterial Outer Membrane Proteins | 3 | 1992 | 406 | 0.150 |
Why?
|
Liposomes | 1 | 2002 | 774 | 0.150 |
Why?
|
Coagulase | 1 | 1998 | 54 | 0.150 |
Why?
|
International Classification of Diseases | 3 | 2012 | 877 | 0.150 |
Why?
|
Massachusetts | 7 | 2022 | 8733 | 0.150 |
Why?
|
Potassium | 1 | 2022 | 1317 | 0.150 |
Why?
|
Bacteremia | 2 | 2010 | 978 | 0.150 |
Why?
|
Staphylococcus | 1 | 1998 | 156 | 0.150 |
Why?
|
Arthroplasty, Replacement, Knee | 2 | 2011 | 1350 | 0.150 |
Why?
|
Bacterial Load | 1 | 2018 | 151 | 0.150 |
Why?
|
Erythromycin | 1 | 2017 | 117 | 0.150 |
Why?
|
Indoles | 2 | 2002 | 1823 | 0.140 |
Why?
|
Diverticulitis | 1 | 2019 | 177 | 0.140 |
Why?
|
Mass Screening | 1 | 2013 | 5411 | 0.140 |
Why?
|
Siderophores | 1 | 2017 | 61 | 0.140 |
Why?
|
Protein Structure, Tertiary | 4 | 2014 | 3797 | 0.140 |
Why?
|
Ventilator-Induced Lung Injury | 1 | 2018 | 119 | 0.140 |
Why?
|
Skin | 5 | 2020 | 4443 | 0.140 |
Why?
|
Sodium | 1 | 2022 | 1594 | 0.140 |
Why?
|
Cefazolin | 2 | 2014 | 94 | 0.140 |
Why?
|
Respiratory Tract Infections | 4 | 2000 | 1000 | 0.140 |
Why?
|
RNA, Messenger | 5 | 2006 | 12755 | 0.140 |
Why?
|
Burkholderia cepacia | 1 | 1996 | 22 | 0.140 |
Why?
|
Male | 39 | 2020 | 356852 | 0.140 |
Why?
|
Zinc | 1 | 2020 | 686 | 0.130 |
Why?
|
B-Lymphocytes | 1 | 2009 | 4707 | 0.130 |
Why?
|
Burkholderia Infections | 1 | 1996 | 40 | 0.130 |
Why?
|
Preoperative Care | 2 | 2020 | 2249 | 0.130 |
Why?
|
Ventilators, Mechanical | 1 | 2018 | 286 | 0.130 |
Why?
|
Genetic Vectors | 1 | 2005 | 3363 | 0.130 |
Why?
|
Drug Hypersensitivity | 2 | 2015 | 905 | 0.130 |
Why?
|
Universal Precautions | 1 | 2015 | 34 | 0.130 |
Why?
|
United States | 16 | 2022 | 71909 | 0.130 |
Why?
|
Biofilms | 2 | 2020 | 617 | 0.130 |
Why?
|
Chloroquine | 1 | 2017 | 278 | 0.130 |
Why?
|
Virulence | 1 | 2019 | 1296 | 0.130 |
Why?
|
Drug Prescriptions | 2 | 2015 | 1663 | 0.120 |
Why?
|
Internship and Residency | 1 | 2015 | 5832 | 0.120 |
Why?
|
Antitoxins | 1 | 2015 | 79 | 0.120 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 559 | 0.120 |
Why?
|
Fungi | 1 | 2017 | 333 | 0.120 |
Why?
|
Gene Knockout Techniques | 1 | 2018 | 800 | 0.120 |
Why?
|
Isopropyl Thiogalactoside | 1 | 2014 | 11 | 0.120 |
Why?
|
Mutagenesis, Site-Directed | 2 | 2010 | 1691 | 0.120 |
Why?
|
Cytotoxins | 1 | 2015 | 153 | 0.120 |
Why?
|
Aged, 80 and over | 16 | 2020 | 58608 | 0.120 |
Why?
|
Bambermycins | 1 | 2014 | 11 | 0.120 |
Why?
|
Phototherapy | 1 | 2017 | 367 | 0.120 |
Why?
|
Two-Hybrid System Techniques | 1 | 2015 | 457 | 0.120 |
Why?
|
Transformation, Bacterial | 3 | 2017 | 77 | 0.120 |
Why?
|
Pyrroles | 1 | 2000 | 1135 | 0.120 |
Why?
|
Female | 39 | 2020 | 388229 | 0.120 |
Why?
|
Workplace | 1 | 2020 | 851 | 0.120 |
Why?
|
Burns | 2 | 2023 | 1853 | 0.120 |
Why?
|
DNA, Superhelical | 1 | 2014 | 51 | 0.120 |
Why?
|
Hospitals, Teaching | 2 | 2015 | 1169 | 0.110 |
Why?
|
Lipopolysaccharides | 2 | 2019 | 2214 | 0.110 |
Why?
|
Disinfection | 1 | 2016 | 211 | 0.110 |
Why?
|
Culture Media | 3 | 2012 | 897 | 0.110 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 3 | 2005 | 1747 | 0.110 |
Why?
|
Peptidoglycan Glycosyltransferase | 1 | 2013 | 66 | 0.110 |
Why?
|
Sequence Homology, Amino Acid | 3 | 2006 | 2754 | 0.110 |
Why?
|
Cephalexin | 1 | 2013 | 37 | 0.110 |
Why?
|
Intensive Care Units | 4 | 2020 | 3710 | 0.110 |
Why?
|
Polyamines | 1 | 2013 | 134 | 0.110 |
Why?
|
Middle Aged | 27 | 2020 | 218357 | 0.110 |
Why?
|
Sequence Alignment | 4 | 2017 | 2174 | 0.110 |
Why?
|
Bioterrorism | 1 | 2013 | 144 | 0.110 |
Why?
|
Enzyme Induction | 1 | 2013 | 455 | 0.110 |
Why?
|
Actinobacteria | 1 | 2013 | 55 | 0.100 |
Why?
|
Aged | 25 | 2020 | 167585 | 0.100 |
Why?
|
Genital Diseases, Male | 2 | 1989 | 83 | 0.100 |
Why?
|
Allergy and Immunology | 1 | 2014 | 173 | 0.100 |
Why?
|
Piperazines | 2 | 2000 | 2506 | 0.100 |
Why?
|
Cell Wall | 3 | 2017 | 423 | 0.100 |
Why?
|
Food Microbiology | 1 | 2012 | 76 | 0.100 |
Why?
|
Mice, Inbred BALB C | 3 | 2020 | 6118 | 0.100 |
Why?
|
Animal Feed | 1 | 2012 | 112 | 0.100 |
Why?
|
Penicillins | 1 | 2015 | 402 | 0.100 |
Why?
|
Citrobacter freundii | 1 | 2011 | 1 | 0.100 |
Why?
|
Nose | 1 | 2015 | 515 | 0.100 |
Why?
|
Amino Acid Substitution | 2 | 2014 | 1736 | 0.100 |
Why?
|
Oligosaccharides | 1 | 2013 | 403 | 0.100 |
Why?
|
Prevalence | 2 | 2020 | 15599 | 0.100 |
Why?
|
Genital Diseases, Female | 2 | 1989 | 191 | 0.100 |
Why?
|
Mycobacterium | 1 | 2013 | 250 | 0.090 |
Why?
|
Pharmacy Service, Hospital | 1 | 2012 | 135 | 0.090 |
Why?
|
Mandatory Reporting | 1 | 2012 | 125 | 0.090 |
Why?
|
Education | 1 | 2014 | 536 | 0.090 |
Why?
|
Communicable Disease Control | 2 | 2020 | 844 | 0.090 |
Why?
|
Sepsis | 2 | 2019 | 2592 | 0.090 |
Why?
|
Blotting, Western | 2 | 2011 | 5040 | 0.090 |
Why?
|
Prosthesis-Related Infections | 2 | 2009 | 484 | 0.090 |
Why?
|
Nalidixic Acid | 3 | 2000 | 19 | 0.090 |
Why?
|
Rabies Vaccines | 1 | 2009 | 28 | 0.090 |
Why?
|
Coronary Artery Bypass | 3 | 2011 | 2269 | 0.090 |
Why?
|
Pyridones | 1 | 1995 | 782 | 0.090 |
Why?
|
Enterococcus faecalis | 1 | 2011 | 247 | 0.090 |
Why?
|
Medical Records | 2 | 2012 | 1403 | 0.090 |
Why?
|
Communicable Diseases, Emerging | 2 | 2009 | 150 | 0.090 |
Why?
|
Public Health Administration | 1 | 2012 | 244 | 0.080 |
Why?
|
Inappropriate Prescribing | 1 | 2012 | 207 | 0.080 |
Why?
|
Proteus Infections | 1 | 2009 | 10 | 0.080 |
Why?
|
Quinolizines | 2 | 2005 | 21 | 0.080 |
Why?
|
Kinetics | 4 | 2008 | 6371 | 0.080 |
Why?
|
Proteus mirabilis | 1 | 2009 | 25 | 0.080 |
Why?
|
Endopeptidases | 2 | 2005 | 772 | 0.080 |
Why?
|
Prostatitis | 1 | 1989 | 102 | 0.080 |
Why?
|
Risk Factors | 9 | 2015 | 73898 | 0.080 |
Why?
|
Drainage | 3 | 2005 | 1157 | 0.080 |
Why?
|
Staphylococcus epidermidis | 3 | 2001 | 120 | 0.080 |
Why?
|
Retrospective Studies | 18 | 2023 | 79746 | 0.080 |
Why?
|
Rifampin | 1 | 2011 | 335 | 0.080 |
Why?
|
Inpatients | 5 | 2019 | 2579 | 0.080 |
Why?
|
Trypanosoma cruzi | 2 | 1989 | 199 | 0.080 |
Why?
|
DNA | 3 | 1993 | 7222 | 0.080 |
Why?
|
Nucleic Acid Amplification Techniques | 2 | 2021 | 330 | 0.080 |
Why?
|
Pneumonia | 1 | 2020 | 2128 | 0.080 |
Why?
|
Dermatitis | 2 | 2009 | 200 | 0.080 |
Why?
|
Light | 3 | 2021 | 1339 | 0.080 |
Why?
|
Policy | 1 | 2012 | 511 | 0.080 |
Why?
|
Mutagenesis, Insertional | 2 | 2001 | 651 | 0.080 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2018 | 2864 | 0.080 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 2 | 1998 | 143 | 0.080 |
Why?
|
History, 21st Century | 1 | 2014 | 1559 | 0.080 |
Why?
|
Mycoplasma Infections | 1 | 1988 | 120 | 0.080 |
Why?
|
Multivariate Analysis | 3 | 2012 | 12160 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3603 | 0.070 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2011 | 1001 | 0.070 |
Why?
|
Gluconates | 1 | 2007 | 30 | 0.070 |
Why?
|
Adult | 19 | 2020 | 218302 | 0.070 |
Why?
|
Binding Sites | 4 | 2017 | 6038 | 0.070 |
Why?
|
Genes, MDR | 1 | 2007 | 36 | 0.070 |
Why?
|
Pneumonia, Bacterial | 1 | 2010 | 316 | 0.070 |
Why?
|
Child | 12 | 2024 | 79418 | 0.070 |
Why?
|
Sensitivity and Specificity | 4 | 2015 | 14654 | 0.070 |
Why?
|
Acetylation | 2 | 2008 | 1050 | 0.070 |
Why?
|
Gene Expression Profiling | 2 | 2014 | 9341 | 0.070 |
Why?
|
Cohort Studies | 7 | 2020 | 41121 | 0.070 |
Why?
|
History, 20th Century | 1 | 2014 | 2760 | 0.070 |
Why?
|
Streptococcus pneumoniae | 2 | 2002 | 724 | 0.070 |
Why?
|
Data Collection | 2 | 2012 | 3306 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5186 | 0.070 |
Why?
|
Sodium Chloride | 2 | 2000 | 597 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3471 | 0.070 |
Why?
|
Point Mutation | 3 | 2013 | 1595 | 0.060 |
Why?
|
Serotyping | 1 | 2006 | 324 | 0.060 |
Why?
|
Fatty Acids | 1 | 2013 | 1803 | 0.060 |
Why?
|
Academic Medical Centers | 3 | 2020 | 2727 | 0.060 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 1996 | 760 | 0.060 |
Why?
|
Office Visits | 1 | 2009 | 592 | 0.060 |
Why?
|
Tetracyclines | 1 | 2005 | 65 | 0.060 |
Why?
|
Permeability | 1 | 2007 | 718 | 0.060 |
Why?
|
Time Factors | 6 | 2012 | 39991 | 0.060 |
Why?
|
Substrate Specificity | 2 | 2008 | 1790 | 0.060 |
Why?
|
Gene Deletion | 1 | 2012 | 2667 | 0.060 |
Why?
|
Pasteurella Infections | 1 | 1984 | 8 | 0.060 |
Why?
|
Prosthesis Implantation | 1 | 2009 | 592 | 0.060 |
Why?
|
Drug Resistance | 2 | 2002 | 1611 | 0.060 |
Why?
|
Temperature | 3 | 2003 | 2208 | 0.060 |
Why?
|
Chromatography, Affinity | 1 | 2005 | 535 | 0.060 |
Why?
|
Enzyme Inhibitors | 3 | 2000 | 3725 | 0.060 |
Why?
|
Nitrogen | 1 | 2005 | 350 | 0.060 |
Why?
|
Gene Frequency | 2 | 2001 | 3588 | 0.060 |
Why?
|
RNA, Bacterial | 1 | 2006 | 383 | 0.060 |
Why?
|
Chromosome Mapping | 4 | 1996 | 4627 | 0.060 |
Why?
|
Molecular Weight | 2 | 2000 | 2182 | 0.060 |
Why?
|
Hydroxyl Radical | 1 | 2023 | 82 | 0.060 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 15228 | 0.060 |
Why?
|
United States Food and Drug Administration | 1 | 2012 | 1668 | 0.060 |
Why?
|
Peptidoglycan | 2 | 2017 | 250 | 0.060 |
Why?
|
Models, Chemical | 1 | 2005 | 615 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2006 | 10806 | 0.060 |
Why?
|
Molecular Structure | 2 | 2017 | 1904 | 0.060 |
Why?
|
Medicare | 2 | 2011 | 6725 | 0.050 |
Why?
|
Genetic Techniques | 1 | 2005 | 428 | 0.050 |
Why?
|
Prospective Studies | 5 | 2022 | 54040 | 0.050 |
Why?
|
Oxidative Stress | 1 | 2014 | 3065 | 0.050 |
Why?
|
Monkeypox virus | 1 | 2022 | 41 | 0.050 |
Why?
|
Cell Line | 1 | 2017 | 15638 | 0.050 |
Why?
|
Skin Tests | 2 | 2015 | 637 | 0.050 |
Why?
|
Wound Infection | 2 | 2016 | 242 | 0.050 |
Why?
|
Biological Availability | 3 | 1998 | 396 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5499 | 0.050 |
Why?
|
Urban Population | 1 | 2010 | 2012 | 0.050 |
Why?
|
Thorax | 1 | 2005 | 552 | 0.050 |
Why?
|
Pilot Projects | 1 | 2015 | 8498 | 0.050 |
Why?
|
Anticoagulants | 1 | 1998 | 4864 | 0.050 |
Why?
|
Blotting, Northern | 1 | 2003 | 1544 | 0.050 |
Why?
|
Odds Ratio | 2 | 2021 | 9719 | 0.050 |
Why?
|
Genetic Linkage | 2 | 2001 | 2383 | 0.050 |
Why?
|
Antigen-Antibody Complex | 1 | 1983 | 512 | 0.050 |
Why?
|
Spores, Fungal | 1 | 2021 | 90 | 0.050 |
Why?
|
Evaluation Studies as Topic | 1 | 2003 | 1636 | 0.050 |
Why?
|
Organoids | 1 | 1987 | 717 | 0.050 |
Why?
|
Mass Spectrometry | 1 | 2008 | 2182 | 0.050 |
Why?
|
Case-Control Studies | 4 | 2011 | 21917 | 0.050 |
Why?
|
Detergents | 1 | 2021 | 234 | 0.050 |
Why?
|
Practice Guidelines as Topic | 2 | 2015 | 7439 | 0.050 |
Why?
|
DNA, Viral | 2 | 2004 | 2184 | 0.050 |
Why?
|
Drug Utilization | 1 | 2007 | 1191 | 0.050 |
Why?
|
Flow Cytometry | 1 | 2011 | 5841 | 0.040 |
Why?
|
Emergency Service, Hospital | 2 | 2012 | 7776 | 0.040 |
Why?
|
Age Distribution | 1 | 2006 | 2888 | 0.040 |
Why?
|
Plankton | 1 | 2020 | 21 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6824 | 0.040 |
Why?
|
Contact Tracing | 1 | 2022 | 267 | 0.040 |
Why?
|
Glutamic Acid | 1 | 2006 | 1161 | 0.040 |
Why?
|
Potassium Chloride | 1 | 2000 | 233 | 0.040 |
Why?
|
Sterilization | 1 | 2001 | 131 | 0.040 |
Why?
|
Fibronectins | 1 | 2003 | 721 | 0.040 |
Why?
|
Phenotype | 3 | 2005 | 16442 | 0.040 |
Why?
|
Catheterization | 1 | 2005 | 1431 | 0.040 |
Why?
|
Sexually Transmitted Diseases, Bacterial | 1 | 2000 | 24 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9113 | 0.040 |
Why?
|
Pneumonia, Pneumococcal | 1 | 2001 | 130 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2014 | 25715 | 0.040 |
Why?
|
Endocarditis, Bacterial | 1 | 1983 | 446 | 0.040 |
Why?
|
Klebsiella | 1 | 1999 | 50 | 0.040 |
Why?
|
Abdomen | 1 | 2005 | 1114 | 0.040 |
Why?
|
Skin Diseases, Bacterial | 1 | 2000 | 68 | 0.040 |
Why?
|
Recurrence | 2 | 2004 | 8456 | 0.040 |
Why?
|
Molecular Epidemiology | 2 | 2013 | 460 | 0.040 |
Why?
|
Quality Control | 1 | 2021 | 822 | 0.040 |
Why?
|
Metals, Heavy | 1 | 2000 | 145 | 0.040 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 16782 | 0.040 |
Why?
|
Phosphorylation | 1 | 2010 | 8312 | 0.040 |
Why?
|
Infection Control Practitioners | 1 | 2018 | 12 | 0.040 |
Why?
|
Serine Endopeptidases | 1 | 2003 | 1018 | 0.040 |
Why?
|
Interferon-gamma | 1 | 2007 | 3123 | 0.040 |
Why?
|
Magnesium | 2 | 1994 | 808 | 0.040 |
Why?
|
Treatment Outcome | 6 | 2020 | 64582 | 0.040 |
Why?
|
Aminocoumarins | 3 | 1989 | 9 | 0.040 |
Why?
|
Biomedical Research | 1 | 2013 | 3390 | 0.040 |
Why?
|
Macromolecular Substances | 1 | 2000 | 1432 | 0.040 |
Why?
|
Streptococcal Infections | 1 | 2002 | 616 | 0.040 |
Why?
|
Drug Interactions | 2 | 1993 | 1419 | 0.040 |
Why?
|
Adolescent | 11 | 2019 | 87297 | 0.040 |
Why?
|
Species Specificity | 1 | 2001 | 2409 | 0.040 |
Why?
|
China | 1 | 2003 | 2343 | 0.040 |
Why?
|
Algorithms | 4 | 2020 | 13940 | 0.040 |
Why?
|
Clindamycin | 1 | 1997 | 139 | 0.030 |
Why?
|
Models, Molecular | 3 | 2013 | 5413 | 0.030 |
Why?
|
Workflow | 1 | 2021 | 843 | 0.030 |
Why?
|
Anesthesiology | 1 | 2007 | 1090 | 0.030 |
Why?
|
Genetic Variation | 2 | 2017 | 6506 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2002 | 858 | 0.030 |
Why?
|
DNA-Directed RNA Polymerases | 1 | 1999 | 368 | 0.030 |
Why?
|
Lasers | 1 | 2001 | 954 | 0.030 |
Why?
|
Selection, Genetic | 1 | 2000 | 871 | 0.030 |
Why?
|
Child, Preschool | 7 | 2013 | 41848 | 0.030 |
Why?
|
Infant | 5 | 2009 | 35828 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 2108 | 0.030 |
Why?
|
Porins | 1 | 2015 | 78 | 0.030 |
Why?
|
Blood Vessel Prosthesis | 1 | 2001 | 939 | 0.030 |
Why?
|
Endophthalmitis | 1 | 1998 | 253 | 0.030 |
Why?
|
Eye Infections, Bacterial | 1 | 1998 | 234 | 0.030 |
Why?
|
Nebulizers and Vaporizers | 1 | 1996 | 138 | 0.030 |
Why?
|
General Surgery | 1 | 2007 | 1660 | 0.030 |
Why?
|
Young Adult | 5 | 2019 | 58143 | 0.030 |
Why?
|
Logistic Models | 3 | 2019 | 13316 | 0.030 |
Why?
|
Reserpine | 1 | 1994 | 60 | 0.030 |
Why?
|
Heart Valve Prosthesis | 1 | 1983 | 1501 | 0.030 |
Why?
|
Safety Management | 1 | 2020 | 760 | 0.030 |
Why?
|
Nucleic Acid Conformation | 3 | 1999 | 896 | 0.030 |
Why?
|
Mitochondria | 1 | 1987 | 3575 | 0.030 |
Why?
|
Sexually Transmitted Diseases | 1 | 2000 | 624 | 0.030 |
Why?
|
Occupational Health | 1 | 2020 | 797 | 0.030 |
Why?
|
Fluorescent Dyes | 1 | 2002 | 1914 | 0.030 |
Why?
|
Tobramycin | 1 | 1993 | 67 | 0.030 |
Why?
|
Verapamil | 1 | 1994 | 242 | 0.030 |
Why?
|
Rodentia | 1 | 1995 | 260 | 0.030 |
Why?
|
Cell Membrane | 1 | 2003 | 3675 | 0.030 |
Why?
|
Adhesins, Escherichia coli | 1 | 2013 | 8 | 0.030 |
Why?
|
RNA, Viral | 1 | 2021 | 2829 | 0.030 |
Why?
|
Clone Cells | 1 | 2017 | 1652 | 0.030 |
Why?
|
Sex Factors | 1 | 2007 | 10491 | 0.030 |
Why?
|
Adenosine Triphosphatases | 1 | 2017 | 833 | 0.030 |
Why?
|
Reference Values | 1 | 2020 | 4919 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2711 | 0.030 |
Why?
|
Length of Stay | 2 | 2016 | 6430 | 0.030 |
Why?
|
Multilocus Sequence Typing | 1 | 2013 | 99 | 0.030 |
Why?
|
Terminology as Topic | 2 | 2012 | 1533 | 0.030 |
Why?
|
Arthritis, Infectious | 2 | 1988 | 343 | 0.030 |
Why?
|
Fimbriae Proteins | 1 | 2013 | 132 | 0.030 |
Why?
|
Breast Implants | 1 | 1996 | 399 | 0.030 |
Why?
|
Cross Reactions | 1 | 2014 | 814 | 0.030 |
Why?
|
Professional Practice | 1 | 2014 | 311 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2017 | 1347 | 0.020 |
Why?
|
Genome, Bacterial | 1 | 2017 | 762 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2007 | 14318 | 0.020 |
Why?
|
Electrophoresis, Agar Gel | 1 | 1991 | 216 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2017 | 3600 | 0.020 |
Why?
|
Health Care Surveys | 2 | 2009 | 2430 | 0.020 |
Why?
|
Disease Notification | 1 | 2011 | 98 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2009 | 21780 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2007 | 10382 | 0.020 |
Why?
|
Endemic Diseases | 1 | 2012 | 186 | 0.020 |
Why?
|
Rectal Diseases | 1 | 2012 | 141 | 0.020 |
Why?
|
Blotting, Southern | 1 | 1991 | 782 | 0.020 |
Why?
|
Restriction Mapping | 1 | 1991 | 852 | 0.020 |
Why?
|
Lipoproteins | 1 | 2015 | 882 | 0.020 |
Why?
|
Insurance Claim Reporting | 1 | 2011 | 164 | 0.020 |
Why?
|
Colonic Diseases | 1 | 2012 | 200 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2021 | 20002 | 0.020 |
Why?
|
Hospitalization | 2 | 2020 | 10683 | 0.020 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39187 | 0.020 |
Why?
|
Treatment Failure | 1 | 2016 | 2636 | 0.020 |
Why?
|
Patient Discharge | 3 | 2011 | 3452 | 0.020 |
Why?
|
Dogs | 2 | 2005 | 3843 | 0.020 |
Why?
|
Patient Compliance | 1 | 2020 | 2683 | 0.020 |
Why?
|
Biological Transport | 1 | 1994 | 2072 | 0.020 |
Why?
|
Spheroplasts | 1 | 1989 | 6 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2007 | 10059 | 0.020 |
Why?
|
Hospital Administration | 1 | 2012 | 353 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 2013 | 6481 | 0.020 |
Why?
|
Prognosis | 2 | 2020 | 29463 | 0.020 |
Why?
|
Rabbits | 4 | 1998 | 4769 | 0.020 |
Why?
|
Stereoisomerism | 2 | 2005 | 623 | 0.020 |
Why?
|
Mycoplasma | 1 | 1988 | 138 | 0.020 |
Why?
|
Protein Structure, Secondary | 1 | 2011 | 1229 | 0.020 |
Why?
|
Administration, Oral | 2 | 1998 | 4019 | 0.020 |
Why?
|
Rhodamine 123 | 1 | 1987 | 36 | 0.020 |
Why?
|
Nifurtimox | 1 | 1987 | 14 | 0.020 |
Why?
|
Aminoglycosides | 1 | 2008 | 163 | 0.020 |
Why?
|
Wounds and Injuries | 1 | 2020 | 2445 | 0.020 |
Why?
|
Rhodamines | 1 | 1987 | 180 | 0.020 |
Why?
|
Genotype | 1 | 2001 | 12876 | 0.020 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1998 | 1623 | 0.020 |
Why?
|
Incidence | 2 | 2020 | 21259 | 0.020 |
Why?
|
Tissue Distribution | 1 | 1991 | 2287 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2011 | 1494 | 0.020 |
Why?
|
Health Personnel | 1 | 2020 | 3284 | 0.020 |
Why?
|
Liver Transplantation | 1 | 1998 | 2292 | 0.020 |
Why?
|
Hysterectomy | 1 | 2012 | 902 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 2936 | 0.020 |
Why?
|
Survival Analysis | 1 | 2019 | 10183 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2012 | 1392 | 0.020 |
Why?
|
Transduction, Genetic | 1 | 1989 | 896 | 0.020 |
Why?
|
Coliphages | 1 | 1985 | 120 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2017 | 2211 | 0.020 |
Why?
|
Colony Count, Microbial | 2 | 1998 | 326 | 0.020 |
Why?
|
Linear Models | 1 | 2016 | 5864 | 0.020 |
Why?
|
Oxazines | 1 | 1987 | 338 | 0.020 |
Why?
|
Muscles | 1 | 1990 | 1580 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 1996 | 2608 | 0.020 |
Why?
|
Pasteurella | 1 | 1984 | 6 | 0.020 |
Why?
|
Risk Assessment | 2 | 2019 | 23956 | 0.010 |
Why?
|
ROC Curve | 1 | 2012 | 3561 | 0.010 |
Why?
|
Half-Life | 1 | 2005 | 651 | 0.010 |
Why?
|
Quality Improvement | 1 | 2019 | 3826 | 0.010 |
Why?
|
F Factor | 1 | 1983 | 12 | 0.010 |
Why?
|
Concurrent Review | 1 | 2003 | 13 | 0.010 |
Why?
|
Software | 1 | 2018 | 4406 | 0.010 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2005 | 325 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5296 | 0.010 |
Why?
|
Self Report | 1 | 2015 | 3677 | 0.010 |
Why?
|
Vascular Diseases | 1 | 2012 | 1178 | 0.010 |
Why?
|
Models, Biological | 2 | 2017 | 9453 | 0.010 |
Why?
|
Prodrugs | 1 | 2005 | 260 | 0.010 |
Why?
|
Bites and Stings | 1 | 1984 | 94 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 1998 | 4148 | 0.010 |
Why?
|
Zoonoses | 1 | 1984 | 179 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2005 | 1383 | 0.010 |
Why?
|
Staining and Labeling | 1 | 1987 | 1094 | 0.010 |
Why?
|
Vascular Surgical Procedures | 1 | 2011 | 1460 | 0.010 |
Why?
|
Cats | 1 | 1984 | 969 | 0.010 |
Why?
|
Hot Temperature | 1 | 1989 | 1432 | 0.010 |
Why?
|
Genes | 1 | 1986 | 1845 | 0.010 |
Why?
|
Rats, Wistar | 1 | 2005 | 1842 | 0.010 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2002 | 108 | 0.010 |
Why?
|
Area Under Curve | 1 | 2005 | 1629 | 0.010 |
Why?
|
Databases, Genetic | 1 | 2008 | 1738 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2018 | 4675 | 0.010 |
Why?
|
Chromosome Deletion | 1 | 1985 | 1387 | 0.010 |
Why?
|
Protein Conformation | 1 | 2008 | 3966 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2005 | 2228 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 1987 | 2663 | 0.010 |
Why?
|
Apoptosis | 1 | 2016 | 9445 | 0.010 |
Why?
|
Bone and Bones | 1 | 1990 | 2552 | 0.010 |
Why?
|
Brain Diseases | 1 | 1988 | 1539 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2015 | 7825 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2013 | 12353 | 0.010 |
Why?
|
Lung | 1 | 1997 | 9924 | 0.010 |
Why?
|
Energy Metabolism | 1 | 1989 | 2860 | 0.010 |
Why?
|
Anterior Eye Segment | 1 | 1998 | 141 | 0.010 |
Why?
|
Signal Transduction | 1 | 2000 | 23254 | 0.010 |
Why?
|
Drug Design | 1 | 2002 | 1064 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2009 | 26034 | 0.010 |
Why?
|
DNA Replication | 1 | 1983 | 1408 | 0.010 |
Why?
|
Vitreous Body | 1 | 1998 | 400 | 0.010 |
Why?
|
Cesarean Section | 1 | 2004 | 1382 | 0.010 |
Why?
|
Genes, Reporter | 1 | 1999 | 1532 | 0.010 |
Why?
|
Mammaplasty | 1 | 2004 | 1216 | 0.010 |
Why?
|
Gene Dosage | 1 | 1999 | 1219 | 0.010 |
Why?
|
Methylmethacrylates | 1 | 1993 | 67 | 0.010 |
Why?
|
Random Allocation | 1 | 1998 | 2389 | 0.010 |
Why?
|
Drug Administration Routes | 1 | 1993 | 150 | 0.010 |
Why?
|
Forecasting | 1 | 2002 | 2928 | 0.010 |
Why?
|
Ilium | 1 | 1993 | 148 | 0.010 |
Why?
|
Age Factors | 1 | 2009 | 18372 | 0.010 |
Why?
|
Methyl Methanesulfonate | 1 | 1989 | 28 | 0.010 |
Why?
|
Nucleic Acid Precursors | 1 | 1989 | 15 | 0.010 |
Why?
|
Rats | 1 | 2005 | 23564 | 0.010 |
Why?
|
Drug Carriers | 1 | 1993 | 702 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2001 | 8558 | 0.000 |
Why?
|
RNA Precursors | 1 | 1989 | 213 | 0.000 |
Why?
|
Retina | 1 | 1998 | 2628 | 0.000 |
Why?
|
Myositis | 1 | 1990 | 269 | 0.000 |
Why?
|
Surgical Flaps | 1 | 1993 | 1661 | 0.000 |
Why?
|
Protein Precursors | 1 | 1989 | 1131 | 0.000 |
Why?
|
Lymphocytes | 1 | 1990 | 2598 | 0.000 |
Why?
|
Microscopy, Electron | 1 | 1985 | 2560 | 0.000 |
Why?
|